Identification of the Effect of Multiple Polymorphisms on the Pharmacokinetics of Simvastatin and Simvastatin Acid Using a Population-Modeling Approach

Ethnic Variability in the Plasma Exposures of OATP1B1 Substrates Such as HMG-CoA Reductase Inhibitors: A Kinetic Consideration of Its Mechanism

(2013) Y Tomita et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Multiple single nucleotide polymorphism analysis using penalized regression in nonlinear mixed-effect pharmacokinetic models

(2013) Julie Bertrand et al.   Pharmacogenetics and Genomics

Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1

(2013) Anne T Nies et al.   Genome Medicine

Understanding the Critical Disposition Pathways of Statins to Assess Drug–Drug Interaction Risk During Drug Development: It's Not Just About OATP1B1

(2012) R Elsby et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

PPARA: A Novel Genetic Determinant of CYP3A4 In Vitro and In Vivo

(2012) Kathrin Klein et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy

(2012) R A Wilke et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A Population Pharmacokinetic-Pharmacodynamic Model for Simvastatin that Predicts Low-Density Lipoprotein-Cholesterol Reduction in Patients with Primary Hyperlipidaemia

(2011) Jimyon Kim et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in The Rotterdam Study

(2011) Laure Elens et al.   Pharmacogenetics and Genomics

Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake

(2011) M. Niemi et al.   PHARMACOLOGICAL REVIEWS

Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

(2010) D Wang et al.   PHARMACOGENOMICS JOURNAL

Human Skeletal Muscle Drug Transporters Determine Local Exposure and Toxicity of Statins

(2009) Michael J. Knauer et al.   CIRCULATION RESEARCH

Transporter Pharmacogenetics and Statin Toxicity

(2009) M Niemi   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm

(2009) Julie Bertrand et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Different effects of theABCG2c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin

(2009) Jenni E Keskitalo et al.   PHARMACOGENOMICS

ABCB1 Haplotypes Differentially Affect the Pharmacokinetics of the Acid and Lactone Forms of Simvastatin and Atorvastatin

(2008) JE Keskitalo et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Comparison of Model-Based Tests and Selection Strategies to Detect Genetic Polymorphisms Influencing Pharmacokinetic Parameters

(2008) Julie Bertrand et al.   Journal of Biopharmaceutical Statistics

SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study

(2008)   NEW ENGLAND JOURNAL OF MEDICINE